INTRODUCTION
Many patients with advanced gastrointestinal stromal tumors (GISTs) who receive treatment with a tyrosine kinase inhibitor (TKI), such as imatinib as first-line therapy and sunitinib as second-line therapy, eventually experience treatment failure. 1, 2 Efforts to optimize drug dosage, 3 blood levels, 4 and compliance 5 may help to further improve the time to progression, but most patients develop a "late" resistance during the course of their disease because of secondary mutations. 6 One strategy to improve the poor outcome of these patients is the development of novel TKIs with an increased activity, particularly against secondary resistance mutations, because c-Kit tyrosine-protein kinase (mast/stem cell growth factor receptor [KIT] ) remains the key oncogenic driver throughout the disease course. 1 Dasatinib inhibits several tyrosine kinases, including breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL), KIT, plateletderived growth factor (PDGF) receptor (PDGFR), protooncogene tyrosine protein kinase Src (SRC), and ephrin (EPH) receptor kinases, at nanomolar concentrations of the drug and displays activity against most imatinibresistant cells. 7, 8 Structurally different from imatinib and sunitinib, 7 it can bind to the adenosine triphosphate (ATP)-binding pocket independent of receptor conformation (active and inactive status) [7] [8] [9] and is not as sensitive as imatinib to conformational changes of the ABL activation loop induced by different mutations. 8 Dasatinib inhibits KIT-dependent activation of downstream pathways important for cell viability and cell survival, such as Ras/mitogen-activated protein kinase, 8 phosphoinositide 3-kinase/Akt, Janus-activated kinases, 10 cellular SRC autophosphorylation in a variety of solid tumor cell lines, [11] [12] [13] [14] and PDGF-induced responses of vascular smooth muscle cells. 15 Also inhibited by dasatinib were the EPH receptor kinases (EPH A and EPH B), which are overexpressed in many malignancies and have important functions in the promotion of angiogenesis, tumor cell motility, invasion, and metastasis.
The safety and efficacy of dasatinib have been established in a large number of patients with chronic myelogenous leukemia who received it as first-line and second-line therapy. 16, 17 Currently, response in patients with GIST is assessed using the Choi criteria, which combine tumor size measurements (Response Evaluation Criteria in Solid Tumors [RECIST]) with density measurements. 18 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) combined with CT (FDG-PET/CT) has become widely used for staging and response assessment in various settings and diseases and is particularly useful in GISTs, because changes in metabolic activity can be detected as early as 24 to 48 hours after the initiation of treatment, 19 and early response assessment with FDG-PET/CT discriminates 2 groups of patients with strongly different prognoses in the first and second lines of treatment. 20 In current trial, we investigated the efficacy of dasatinib in untreated patients with GISTs. The primary endpoint was the response rate as assessed by FDG PET/CT fusion scans 4 weeks after the start of treatment.
MATERIALS AND METHODS

Study Objectives and Design
The primary objective of this trial was to assess the efficacy of dasatinib in patients with untreated, advanced GISTs. Patients received oral dasatinib 70 mg twice daily as the starting dose and continued until they developed disease progression or unacceptable toxicity for a maximum of 2 years (26 cycles, with each cycle lasting 4 weeks). Dasatinib was withheld for grade 3 toxicity and was restarted upon recovery to grade 1 toxicity at the next lower dose level (50 mg twice daily, 100 mg once daily). Patients who sustained complete or partial remission after 2 years could continue dasatinib or switch to imatinib or any other standard treatment at the discretion of their treating physician. Elective surgery was allowed after the completion of at least 6 cycles of dasatinib treatment in responding and stabilized patients. Key eligibility criteria were histologically confirmed diagnosis of advanced GIST; a tumor that was metabolically active on baseline FDG-PET/CT imaging; and patients who had not previously received any TKIs. Disease had to be measurable by conventional scans (CT or magnetic resonance imaging [MRI] ). Adult patients who had a good performance status (World Health Organization performance status, 0-2) and adequate hematologic and organ function values, had no previous malignancy within 5 years, and had no clinically significant cardiovascular disease or other concurrent medical condition, including pleural or pericardial effusions, coagulation or platelet function disorder, ongoing significant gastrointestinal bleeding, nausea, vomiting, or malabsorption syndrome, were eligible to participate in this trial. The use of antacids was not permitted; and it was recommended that, if possible, patients should discontinue intravenous bisphosphonates, cytochrome P450 3A4 inducers/inhibitors, or medications that prolonged QT.
FDG-PET/CT images were obtained at 2, 3, 4, 7, 10, and 13 months after the start of treatment; and CT or MRI scans were obtained every 3 months after the start of treatment. In the second year, only CT or MRI scans were required, but any suspected progression had to be confirmed by PET/CT studies (see Supporting Fig. 1 ). All PET imaging data had to be transmitted for central review on the next working day at the latest. FDG-PET qualification with uniform phantom was mandatory before trial participation to verify the accuracy of standardized uptake values (SUVs) and was repeated every 3 months and after any PET/CT maintenance.
The primary endpoint was response as assessed by fusion PET/CT scan according to European Organization for Research and Treatment of Cancer PET Study Group criteria 21 at 4 weeks compared with baseline. The PET response was classified into 4 categories based on the change in the SUV from baseline to week 4: A metabolic complete response indicated the disappearance of all visible FDG activity on PET (SUV not more than surrounding tissues); a metabolic partial response denoted a decrease 25% in the SUV, metabolic stable disease indicated changes in the SUV between 225% and 125%, and metabolic progressive disease indicated an increase 25% in the SUV or the appearance of new tumoral lesions. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. 22 
Statistics
Clinical data were collected and assessed according to the statistical analysis plan as outlined in the trial protocol. A Simon 2-stage optimal design was used. A response rate of p0 5 0.5 was considered uninteresting, and p1 5 0.7 was considered promising. Because the trial was closed in stage 2 before the planned accrual was reached, the new decision limit and the power for an exact 2-stage binomial test with N 5 42 and R 5 26 was 79.2% with a significance level of a 5 .038.
All 42 patients were assessed for safety, treatment response, and survival. The date of data cutoff was May 22, 2017. Progression-free survival (PFS) was calculated from the date of dasatinib initiation to disease progression or death from any cause, and overall survival (OS) was calculated from the date of first dasatinib administration to death. 23 The time to event was analyzed according to a univariate Cox proportional-hazards model if not otherwise stated. Kaplan-Meier 24 curves are presented, and survival between groups was compared using the log-rank test. Dotted lines in Figures 1 and 2 indicate 95% confidence intervals (CIs). Statistical calculations were done using SAS STAT version 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
Patients
The trial opened on January 17, 2008, and was closed early on November 30, 2011 because of slow accrual. During this period, 47 of 52 initially planned patients were included. Five patients were ineligible (n 5 2, not GISTs; n 5 2, baseline PET-negative on central review; n 5 1, no baseline CT). The median patient age was 61 years, 24 patients were men, and 18 were women. Twenty-nine patients had a performance status of 0, and 13 had a performance status of 1. Mutational data were available for 34 patients. Twenty-five patients had a KIT exon 11 mutation, 1 had a KIT exon 9 mutation, 1 had a PDGFRA exon 18 mutation (Asp842_His845del4), and 7 had wild type tumors. Seventy-six percent of patients had metastatic GISTs of either gastric or small intestinal origin (Table 1) . Forty-two patients received treatment at 13 centers in 4 European countries and have received a total of 460 cycles (median, 9 cycles; minimum, 1 cycle; maximum, 26 cycles). These patients were analyzed for safety and efficacy.
FDG-PET Quality Assurance
One center (8%) needed recalibration of their FDG-PET scanner before trial participation. Including longitudinal 
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Cancer April 1, 2018 monitoring, 6% of 1482 measurements were out of range and required recalibrations of the FDG-PET scanner. 25 
Efficacy
At a median follow-up of 67.2 months, all patients were off trial. However, 4 patients continued drug beyond 2 years. Patients went off trial for elective surgery (n 5 8), after 26 cycles according to protocol (n 5 5), after disease progression (n 5 14), after toxicity (n 5 7), and for other reasons (n 5 5); and 3 patients died (cardiac arrest, non-GIST upper gastrointestinal bleeding, out of hospital; n 5 1 each). The FDG-PET/CT response rate (complete plus partial responses [CR 1 PR]) at 4 weeks was 74% (95% CI, 56%-85%; CR, n 5 14; PR, n 5 17; stable disease, n 5 6; progressive disease, n 5 3; not evaluable, n 5 2). The best FDG-PET responses (CR 1 PR) were 77% overall (n 5 42), 80% in patients with a KIT exon 11 mutation (n 5 25), and 71% in those with wild-type GIST (n 5 7). The median PFS was 13.6 months (95% CI, 5.7-21.7), and the median OS was not reached. At 48 months, 74% of patients remained alive (95% CI, 60%-91%) (Figs. (1 and 2) ).
Tolerability
Five percent of all patients experienced grade 4 toxicity, and 38% experienced grade 3 toxicity. These toxicities most often were gastrointestinal or pulmonary (mainly pleural effusions and/or dyspnea). Pulmonary hypertension was not observed. Twenty-eight patients had their dose reduced or interrupted.
DISCUSSION
In patients with advanced GIST, early and late resistance to first-line treatment with imatinib 2 prompted a search for therapeutic alternatives. Dasatinib, which is structurally different from imatinib, had demonstrated low inhibitory concentrations and efficacy against mutants (cell lines) resistant to imatinib and activity against several targets and pathways. [7] [8] [9] [10] [11] [12] [13] [14] [15] Therefore, a window-of-opportunity trial 26 investigating dasatinib in untreated patients seemed to be warranted. To avoid potential under-treatment, early response assessment with FDG-PET/CT 20, 27 imaging was an integral part of the study design and was chosen as the primary endpoint. In our experience, FDG-PET/CT was very useful for early response assessment, but we would recommend mandatory center qualification and repeated longitudinal SUV accuracy monitoring.
Seventy-seven percent of all patients responded to dasatinib. Exploratory analyses of differential responses in specific mutations (KIT exons 11 and 9, wild type, PDGFRA) to dasatinib revealed no differences. None of the patients had the PDGFRA exon 18 aspartic acid to valine substitution at position 842 (D842V) mutation, which is considered TKI-resistant but potentially responsive to dasatinib. 28 We can only speculate whether less toxicity would have been observed in this trial with the current, standard 100 mg once daily dasatinib schedule instead of the 2 3 70 mg per day trial regimen. Dyspnea and pleural effusions were the most frequent all grade adverse events observed, followed by fatigue and diarrhea.
The median PFS of 13.6 months was lower than what has been reported in phase 3 trials with imatinib, 29, 30 but the small number of patients who received treatment may explain this finding. Eight of 42 patients underwent curative surgery after responding to dasatinib treatment, which may have had a positive impact on OS, which has not yet been reached.
With few exceptions, patients today receive standard doses of imatinib in the first line, sunitinib in the second line, and regorafenib in the third line. 31 This soon may change. Improved molecular diagnostics and circulating tumor DNA analysis 32, 33 might allow the selection of a TKI according to a patient's individual primary and secondary mutations. Dasatinib might be of particular use in patients who have PDGFRA exon 18 mutations and SRC expression, as suggested by preliminary data from the SARC 09 trial investigating dasatinib in the third-line or fourth-line setting. 34 Finally, additional drugs and treatment lines might prolong survival simply because any TKI treatment is better than best supportive care, 35 and TKIs that have not been used in prior treatment lines could be of particular interest here. On the basis of our data in a limited number of patients, we conclude that dasatinib might be used in specific mutations and as an additional line of treatment to increase OS rather than as first-line treatment in patients with GIST.
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